Fampridine Application Scope

Fampridine is indicated for the symptomatic improvement of walking in adult patients with multiple sclerosis (MS) who have a walking disability. Treatment should be initiated and supervised by physicians experienced in the management of MS.

fampridine

Fampridine Characteristics

Ingredients: Each extended-release tablet contains 10 mg of fampridine (4-aminopyridine) as the active ingredient.
Specification: Extended-release tablets, 10 mg.
Packaging Specification: Available in bottles of 60 tablets (60-count, 60 cc HDPE round bottles) and physician samples packaged in 14-count (30 cc HDPE round bottles).
Storage: Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F).
Expiry Date: 36 months from the date of manufacture.
Executive Standard: Manufactured in compliance with FDA-approved standards.
Approval Number: NDA 22-250.
Date of Revision: December 23, 2009.
Manufacturer: Acorda Therapeutics, Inc.

Guidelines for the Use of Fampridine

Dosage and Administration: The recommended dose is one 10 mg tablet taken twice daily, approximately 12 hours apart. Tablets should be swallowed whole; do not divide, crush, chew, or dissolve. Fampridine can be taken with or without food. If a dose is missed, do not take double or extra doses.
Adverse Reactions: Common adverse reactions include urinary tract infections, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain. There is a dose-related increased risk of seizures.
Contraindications: Is contraindicated in patients with a history of seizures, moderate or severe renal impairment (creatinine clearance ≤50 mL/min), or hypersensitivity to fampridine or any of its components.
Precautions: Assess renal function before initiating treatment and monitor periodically. Use with caution in patients with factors that may lower the seizure threshold. Discontinue use if a seizure occurs during treatment.

Interactions

Drug Interactions: Fampridine is primarily excreted unchanged by the kidneys. Concomitant use with drugs that are inhibitors of the organic cation transporter 2 (OCT2), such as cimetidine and quinidine, is contraindicated due to the potential for increased fampridine plasma concentrations. Use with caution when co-administered with other drugs that can affect renal function.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.